1 min.Read

Mounjaro Shows Heart-Health Benefits in Major Diabetes Study

August 1, 2025

In a significant development for diabetes and cardiovascular care, Eli Lilly has announced that its drug Mounjaro (tirzepatide) has demonstrated clear heart-health benefits in patients with type 2 diabetes and existing cardiovascular disease.

📢 The findings — from a large-scale head-to-head trial — were released on July 31, 2025, and may pave the way for an FDA label update.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Key Highlights: Major Indian Pharma Companies – July 2025

Can Medicines Inject the Vitamins Amazon is Missing?

Mounjaro Shows Heart-Health Benefits in Major Diabetes Study

Free Membership Required

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Topics

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

MedicinMan Pharma Pulse: August 2026

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Related Articles

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Company

Headlines

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Newsletter